Connor, Clark & Lunn Investment Management Ltd. Lineage Cell Therapeutics, Inc. Transaction History

Connor, Clark & Lunn Investment Management Ltd.

$18.8 Billion
Q3 2024

A detailed history of Connor, Clark & Lunn Investment Management Ltd. transactions in Lineage Cell Therapeutics, Inc. stock. As of the latest transaction made, Connor, Clark & Lunn Investment Management Ltd. holds 191,436 shares of LCTX stock, worth $95,718. This represents 0.0% of its overall portfolio holdings.

Number of Shares

191,436

Previous 207,764 7.86%

Holding current value

$95,718

Previous $207,000 15.94%

% of portfolio

0.0%

Previous 0.0%

16 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2024 Nov 08, 2024	SELL	$0.8 - $1.12 $13,062 - $18,287	-16,328 Reduced 7.86%	191,436 $174,000
Q2 2024 Aug 09, 2024	BUY	$0.89 - $1.47 $1,353 - $2,235	1,521 Added 0.74%	207,764 $207,000
Q1 2024 May 09, 2024	BUY	$0.86 - $1.48 $37,461 - $64,468	43,560 Added 26.78%	206,243 $305,000
Q4 2023 Feb 09, 2024	SELL	$0.91 - $1.35 $18,088 - $26,835	-19,878 Reduced 10.89%	162,683 $177,000
Q3 2023 Nov 13, 2023	SELL	$1.16 - $1.53 $82,028 - $108,192	-70,714 Reduced 27.92%	182,561 $215,000
Q2 2023 Aug 10, 2023	BUY	$1.26 - $1.53 $15,438 - $18,747	12,253 Added 5.08%	253,275 $357,000
Q1 2023 May 09, 2023	SELL	$1.2 - $1.53 $25,056 - $31,946	-20,880 Reduced 7.97%	241,022 $361,000
Q4 2022 Feb 10, 2023	SELL	$1.02 - $1.5 $26,924 - $39,595	-26,397 Reduced 9.16%	261,902 $306,000
Q3 2022 Nov 10, 2022	BUY	$1.13 - $1.77 $172,857 - $270,758	152,971 Added 113.04%	288,299 $326,000
Q2 2022 Aug 05, 2022	BUY	$1.12 - $1.61 $138,127 - $198,558	123,328 Added 1027.73%	135,328 $214,000
Q1 2022 May 12, 2022	BUY	$1.21 - $2.48 $14,520 - $29,760	12,000 New	12,000 $18,000
Q4 2020 Feb 16, 2021	SELL	$0.95 - $1.83 $13,870 - $26,719	-14,601 Closed	0 $0
Q3 2020 Nov 12, 2020	SELL	$0.75 - $1.09 $31,455 - $45,714	-41,940 Reduced 74.18%	14,601 $14,000
Q2 2020 Aug 13, 2020	BUY	$0.71 - $1.18 $4,134 - $6,871	5,823 Added 11.48%	56,541 $49,000
Q1 2020 May 13, 2020	BUY	$0.6 - $1.58 $17,140 - $45,137	28,568 Added 128.98%	50,718 $42,000
Q4 2019 Feb 12, 2020	BUY	$0.54 - $1.01 $11,961 - $22,371	22,150 New	22,150 $20,000

Others Institutions Holding LCTX

# of Institutions

121

Shares Held

94.2M

Call Options Held

63.8K

Put Options Held

View Full List

About Lineage Cell Therapeutics, Inc.

Ticker LCTX
Exchange NYSE
Sector Healthcare
Industry Biotechnology
Shares Outstandng 169,755,008
Market Cap $84.9M
Description
Lineage Cell Therapeutics, Inc., a clinical-stage biotechnology company, develops novel cell therapies for the treatment of degenerative diseases in the United States and internationally. The company develops OpRegen, a retinal pigment epithelium cell replacement therapy, which is in Phase I/IIa clinical trial for the treatment of the dry age-re...

More about LCTX

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Connor, Clark & Lunn Investment Management Ltd., based on Form 13F filings with the SEC.

News

Stay updated on Connor, Clark & Lunn Investment Management Ltd. with notifications on news.

Account

Connor, Clark & Lunn Investment Management Ltd. Lineage Cell Therapeutics, Inc. Transaction History